Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Recombinant Human VEGFC

Cat.No. : VEGFC-157H
Product Overview : Recombinant Human vascular endothelial growth factor C was expressed in modifiedhuman 293 cells.
  • Specification
  • Gene Information
  • Related Products
Cat. No. : VEGFC-157H
Description : Vascular endothelial growth factor C (VEGF-C), also known as Flt4 ligand (Flt4-L), vascular endothelial growth factor-related protein (VRP) and VEGF-2, is a member of the cysteine-knot growth factor superfamily and exhibits homology with VEGF-121 (32%) and PDGF (27%). However VEGF-C also possesses a 180 amino acid C-terminal cysteine-rich domain absent in other VEGFs. The major secreted form of VEGF-C is a disulfide linked antiparallel homodimeric protein containing 5 potential N-linked glycosylation sites and has a theoretical molecular weight of 44 kDa. VEGF-C is predominantly involved in angiogenesis, vasculogenesis, lymphangiogenesis as well as an inhibitor of dendritic cell maturation. VEGF-C also possesses both mitogenic and chemotactic activity w.r.t. endothelial cells and monocytes.
Source : human 293 cells.
Molecular Mass : VEGF-C secreted antiparallel homodimer migrates between 45 and 55 kDa due to post-translational modifications, in particular glycosylation. This compares with the unmodified homodimer that has a predicted molecular mass of 43.9 kDa. Individual chains of VEGF-C migrate as a band between 27 and 35 kDa in SDS-PAGE due to post-translational modifications, in particular glycosylation. This compares with the unmodified VEGF-C chains that have a predicted molecular mass of 21.6 and 22.2 kDa.
PI : VEGF-C secreted antiparallel homodimer separates into a number of isoforms with a pI between 5.6 and 8.4 in 2D PAGE due to post-translational modifications, in particular glycosylation. This compares with the unmodified VEGF-C homodimer that has a predicted pI of 7.8.
% Carbohydrate : VEGF-C consists of 15-40% from 1D gel of individual chains carbohydrate by weight.
Glycosylation : VEGF-C contains N- and probably O-linked oligosaccharides.
Purity : >95%, as determined by SDS-PAGE and visualized by silver stain.
Formulation : When reconstituted in 0.5 ml sterile phosphate-buffered saline, the solution will contain 1% human serum albumin (HSA) and 10% trehalose.
Reconstitution : It is recommended that 0.5 ml of sterile phosphate-buffered saline be added to the vial.
Storage : Lyophilized products should be stored at 2 to 8°C. Following reconstitution short-term storage at 4°C is recommended, and longer-term storage of aliquots at -18 to -20°C.
Gene Name : VEGFC vascular endothelial growth factor C [ Homo sapiens ]
Synonyms : vascular endothelial growth factor C; VRP; Flt4-L; VEGFC; FLT4 ligand DHM; vascular endothelial growth factor-related protein; VEGF-C; Flt4 ligand; Vascular endothelial growth factor-related protein
Gene ID : 7424
mRNA Refseq : NM_005429
Protein Refseq : NP_005420
MIM : 601528
UniProt ID : P49767
Chromosome Location : 4q34.3
Pathway : Bladder cancer; Cytokine-cytokine receptor interaction; Focal adhesion; Pancreatic cancer; Pathways in cancer; Renal cell carcinoma; mTOR signaling pathway; Hemostasis; Signaling by VEGF
Function : growth factor activity; vascular endothelial growth factor receptor 3 binding

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (7)

Ask a question
What signaling mechanisms are involved in VEGFC and its receptor interactions? 05/21/2022

VEGFC primarily signals through its interactions with VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2) and VEGFR-3. Upon binding to one of these receptors, VEGFC triggers receptor dimerization, leading to the activation of intracellular signaling pathways. This activation involves phosphorylation events and subsequent recruitment of downstream effectors, which ultimately regulate cellular responses such as proliferation, migration, and angiogenesis. The intricate signaling mechanisms underlying VEGFC-receptor interactions contribute to its functional versatility and provide potential targets for therapeutic interventions.

What is known about the structural characteristics of VEGFC and its precursor? 03/29/2022

VEGFC protein is derived from the conversion of proVEGFC precursor protein and comprises approximately 354 amino acid residues. Structurally, it consists of a signal sequence, an N-terminal domain, and a C-terminal VEGF homology domain. The signal sequence is involved in cellular localization and secretion processes, while the VEGF homology domain interacts with target receptors, mediating cellular proliferation and angiogenesis. Understanding the specific structural features is crucial for elucidating the functional properties and molecular interactions associated with VEGFC.

How does VEGFC contribute to pathological conditions, particularly in cancer? 12/06/2021

VEGFC's involvement in pathological conditions, including cancer, is extensively studied. The upregulation of VEGFC expression in tumor cells promotes angiogenesis and lymphangiogenesis within the tumor microenvironment. This enhanced blood and lymphatic vessel formation facilitates tumor growth, invasion, and metastasis. Moreover, VEGFC can induce lymphangiogenesis in sentinel lymph nodes, aiding cancer cell dissemination. Targeting VEGFC signaling pathways has emerged as a potential therapeutic strategy to inhibit tumor angiogenesis and lymphangiogenesis, highlighting the clinical significance of understanding the complex interplay between VEGFC and cancer progression.

What are the current therapeutic interventions targeting VEGFC and its downstream signaling pathways? 04/22/2021

Several therapeutic interventions targeting VEGFC and its downstream signaling pathways are under investigation. Anti-VEGFC monoclonal antibodies, VEGFR inhibitors, and small molecule inhibitors of VEGFC-mediated signaling have shown promise in preclinical and clinical studies. These interventions aim to disrupt the angiogenic and lymphangiogenic processes driven by VEGFC, thereby inhibiting tumor growth, metastasis, and other pathological conditions associated with VEGFC dysregulation. Additionally, exploring combinational approaches with existing therapies, such as chemotherapy and immunotherapy, holds potential for synergistic effects and improved treatment outcomes. Continued research efforts are focused on optimizing these interventions for clinical application and expanding the therapeutic repertoire for VEGFC-associated diseases.

Are there any known regulatory mechanisms that modulate VEGFC expression levels? 08/20/2020

Multiple regulatory mechanisms control VEGFC expression levels. Transcriptional regulation plays a significant role, with various transcription factors binding to the VEGFC promoter region to activate or suppress its transcription. Additionally, post-transcriptional regulation through microRNAs and RNA-binding proteins can modulate VEGFC mRNA stability and translation efficiency. Furthermore, environmental factors, such as hypoxia and inflammation, influence VEGFC expression by activating specific signaling pathways. Understanding the precise regulatory mechanisms is crucial for deciphering the intricate balance required for maintaining proper VEGFC levels and ensuring its functional integrity.

What are the clinical implications of VEGFC dysregulation? 05/08/2020

Dysregulation of VEGFC has been associated with various pathological conditions. Excessive VEGFC expression has been implicated in tumor angiogenesis, promoting the growth and spread of cancer cells by stimulating the formation of blood and lymphatic vessels in the tumor microenvironment. On the other hand, decreased or insufficient VEGFC levels have been linked to lymphatic disorders, such as lymphedema, where impaired lymphatic vessel development results in fluid buildup and tissue swelling. Additionally, alterations in VEGFC signaling have been observed in ocular diseases, inflammatory disorders, and cardiovascular diseases. Understanding the dysregulation of VEGFC in these contexts may pave the way for potential therapeutic strategies targeting this protein.

What are the cellular functions of VEGFC and its involvement in physiological processes? 05/30/2017

VEGFC (Vascular Endothelial Growth Factor C) has diverse cellular functions. Primarily, it serves as a potent angiogenic factor, participating in neovascularization and lymphangiogenesis processes. VEGFC also regulates endothelial cell proliferation and migration, playing a crucial role in lymphatic dissemination and metastasis. Additionally, VEGFC is implicated in neurodevelopment, mammary gland morphogenesis, tissue regeneration, and other physiological processes. Its multifaceted functions highlight its significance in various biological contexts, emphasizing the need for further investigation to unravel its precise mechanisms and implications.

Customer Reviews (3)

Write a review
Reviews
02/12/2021

    Embodied with the glorious power of scientific progress, the innovation behind this reagent inspires truly remarkable experimental encounters.

    02/21/2018

      By requiring minimal usage, this protein reagent significantly reduces consumable costs, making it an ideal choice for large-scale experiments.

      03/26/2016

        The manufacturer's proactive approach in offering valuable insights and suggestions has greatly improved the outcome of my experiments.

        Ask a Question for All VEGFC Products

        Required fields are marked with *

        My Review for All VEGFC Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends